Stratified Medicine in primary Sjögren’s syndrome

Objectives of the Project

The proposal aims to further characterise the clinical significance and the underpinning pathotypes of 4 PSS subtypes. The specific objectives are:

1. To understand the natural history of the different PSS subtypes.

2. To validate the transcriptomic signatures of the PSS subtypes and re-calibrate (if necessary) for non-UK cohorts.

3. To further characterise the underpinning pathobiological profiles of the four PSS subtypes

4. To explore whether the four subtypes respond differently to treatments by reanalysing data from two clinical trials (JOQUER (hydroxychloroquine) and TRACTISS (Rituximab)

Facts and Figures

Project lead
Prof. W-F Ng
Newcastle University
FOREUM research grant: € 600.000
2018, Duration 3 years

Meet the Team

Mr. D Lendrem
Newcastle University
Prof. J-E Gottenberg
Strasbourg University
Prof R Seror
Université Paris Sud INSERM U1184
Prof. V Devauchelle-Pensec
Brest University
Prof. A Saraux
Brest University
Hon Prof. S Bowman
University of Birmingham
Dr. F Barone
University of Birmingham
Dr. B Fisher
University of Birmingham
Assoc. Prof. G Nordmark
Uppsala University
Prof. U Landegren
Uppsala University
Prof. R Omdal
Stavanger University Hospital
Dr. M Bombardieri
Queen Mary University London

Patient Voice

We will invite two patient research partners from each participating country to advise on what information to collect that will best describes the burden that PSS brings to their daily lives. It will involve an initial face-to-face meeting followed by two video-conferences. We will also invite two of them to join our steering committee to provide guidance and oversight of the whole proposal.